• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.


    Find out more about it and REGISTER today!

  • 2019 Senior Report Senior Report: Older Americans have more options for home care, but still struggling.

    The United Health Foundation has released results of a sweeping new study benchmarking the health of older adults. The America's Health Rankings® Senior Report was created in partnership with GAPNA to improve the health of America's seniors.

    The data will help advanced practice nurses and other providers deliver quality care.

    Find out about it!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • FREE continuing education credit is available for the following session:

    "Dementia Management Update"

    (session captured at the GAPNA 2018 Annual Conference)

    For September/October 2019 - Get Your Free CNE Now!

Elderly Patients with Colon Cancer at Risk for Various Treatment-Related Toxicities

Patients who receive surgery for stage III colon cancer can benefit from 5-flurouracil (5-FU)-based chemotherapy.

However, 5-FU-based chemotherapy is associated with increased risk of developing gastrointestinal, blood, and cardiac toxicities in elderly patients with colon cancer. These patients need to be monitored closely so that the benefits of chemotherapy can outweigh the risks, suggest the study authors.

In a study of 12,099 patients with stage III colon cancer, patients receiving chemotherapy were more likely to be younger, married, and have fewer coexisting conditions than the untreated group.

This difference was most pronounced for age, with 88.2% of patients aged 65-69 initiating chemotherapy compared to just 18.1% of patients aged 85 and older.

During 3 months after surgery, the cumulative incidence rate of toxicities was 9.1% in the chemotherapy group and 4.3% in the non-chemotherapy group.

Common toxicities included volume depletion disorder, agranulocytosis, diarrhea, nausea, and vomiting. Women were 35% more likely to experience toxicities than men and Blacks were 35% less likely to develop toxicities than Whites.

Chemotherapy was only slightly associated with the risk for developing heart disease.

For more info, see Hu, C-Y. et al. (2012). Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. American Journal of Clinical Oncology, 35(3), 228-236.

Related Topic 1: 

GAPNA Newsletter Issue: